share_log

HC Wainwright & Co. Initiates Coverage On Enliven Therapeutics With Buy Rating, Announces Price Target of $37

HC Wainwright & Co. Initiates Coverage On Enliven Therapeutics With Buy Rating, Announces Price Target of $37

HC韋恩賴特公司開始對Enliven Therapeutics進行買入評級,宣佈目標股價爲37美元
Benzinga ·  2024/09/09 19:27  · 評級/大行評級

HC Wainwright & Co. analyst Robert Burns initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Buy rating and announces Price Target of $37.

HC韋恩賴特分析師羅伯特·伯恩斯啓動了對Enliven Therapeutics(納斯達克:ELVN)的覆蓋,並給予買入評級,宣佈目標股價爲37美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論